Cadila Healthcare Limited

10/22/2021 | Press release | Distributed by Public on 10/22/2021 07:03

zydus announces ‘first patient’ randomised in EVIDENCES-X TM Phase II(b) clinical trial of Saroglitazar Mg in NASH

www.zyduscadila.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete.

Reference ID IP Address Date and Time
8946b0739bb182bd1a59ff3123401467 18.188.216.125 10/22/2021 01:03 PM UTC